Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience.

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes. Cytopenias were observed in clinical trials with both products; however, little is known regarding the patterns and outcomes of these cytopenias. We reviewed DLBCL patients ( Median duration of leukopenia, neutropenia, lymphopenia, anemia, and thrombocytopenia was 49, 9, 117.5, 125, and 95.5 days after CAR-T infusion, respectively. Filgrastim was used in 63% of patients, and 50% of patients received red cell or platelet transfusions. With the exception of neutropenia, increase in the duration of cytopenia of any lineage was associated with improvement in progression-free survival, and in overall survival in case of anemia. There was no association between the duration of cytopenias with either cytokine release syndrome or neurotoxicity. Our data suggest a correlation between cytopenias and survival outcomes after CD19 CAR-T therapy. If validated, cytopenia may be proven useful as a biomarker of response and survival after CAR-T therapy.

Informations de copyright

© 2021 Schaefer et al.

Déclaration de conflit d'intérêts

Dr Adam Kittai reports personal fees from Bristol-Myers Squibb, outside the submitted work. Dr Ayman Saad reports personal fees from Magenta Therapeutics, Incyte pharamceuticals, and CareDx, outside the submitted work. Dr Samantha M Jaglowski reports grants and/or personal fees from Novartis, Kite, CRISPR Therapeutics, Takeda, Juno, and Unum Therapeutics, during the conduct of the study. The authors report no other conflicts of interest in this work.